Skip to Content

Posts tagged with "The Dark Side"

  • Regulatory Affairs

    Selling Zyprexa

    Well, this doesn’t look good for Lilly. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa’s off-label promotion. The company has already paid some serious fines, and is now fighting it out with insurance companies and other plaintiffs who are seeking to recover their costs. Several states are suing… Read More
  • The Dark Side

    Another Sack of Raving Nonsense Is Slated For Publication

    I spoke here about Scigen, the program that’ll concoct a load of total nonsense for you and make it look – from a distance – like a journal paper. It’s a surprisingly valuable tool, since the scientific publishing world apparently has a bigger demand for total nonsense than you might think, especially after the checks… Read More
  • The Dark Side

    Word For Word – But Why?

    I missed this a couple of months ago, but there was a paper withdrawn from the Journal of Organic Chemistry. The original is here, a contribution from the Indian Institute of Chemical Technology in Hyderabad on 2-aryl benzothiazoles. The JOC editor’s note is here, and states: This manuscript was withdrawn from publication by the Editor-in-Chi… Read More
  • Business and Markets

    Perpetual Patents: A Nasty Thought Occurs

    A colleague of mine read the “Perpetual Patent” item below, and had a thought of his own. “If I were the head of a company that just discovered something like Lipitor”, he said, using the example that the Xconomy piece used as well, “I’m probably going to fire all the early stage research people. Who… Read More
  • Academia (vs. Industry)

    Competing (And Competing Unethically?)

    Sean Cutler, a biologist at UC-Riverside, is the corresponding author of a paper in a recent issue of Science. That’s always a good thing, of course, and people are willing to go to a lot of trouble to have something like that on their list of publications. But Cutler’s worried that too many scientists, especially… Read More
  • Business and Markets

    Merck, Elsevier, and Fakery

    I’ve been meaning to write about the latest advance in salesmanship, pioneered by Merck and Elsevier. As most of you will have heard, the two collaborated to produce something called “The Australasian Journal of Bone and Joint Medicine”. This appears to have looked like a real journal, complete with the Elsevier logo and a board… Read More
  • Biological News

    No MAGIC Involved

    What a mess! Science has a retraction of a 2005 paper, which is always a nasty enough business, but in this case, the authors can’t agree on whether it should be retracted or not. And no one seems to be able to agree on whether the original results were real, and (even if they weren’t) Read More
  • Clinical Trials

    What Results Did You Have In Mind?

    Of course, no sooner do I come out defending drug company research than we have this to think about: “An influential Harvard child psychiatrist told the drug giant Johnson & Johnson that planned studies of its medicines in children would yield results benefiting the company, according to court documents dating over several years that the… Read More
  • Clinical Trials

    Drug Industry Research: Reliable or Not?

    So, in light of the Reuben scandal of forged data about pain management in surgery patients, the question naturally comes to mind: how much role did industry play? I’ve seen articles (and had comments here) to the effect that industry-sponsored research is worthless: discount it, can’t trust it, bought and paid for, and so on. Read More
  • The Dark Side

    Fraud: How, and Why, and How Again

    Readers may have seen the recent stories of an academic anaesthesiologist, Dr. Scott Reuben, who published an entire string of fraudulent papers in the pain management field. Various rabble-rousing sources have used this as a chance to run “Big Pharma Pays For Deception” stories, but I’m not going to give that angle much time at… Read More